Brokerage Firm Rating Update on Baxter International (BAX)

Baxter International (BAX) : 11 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Baxter International (BAX) : The most positive equity analysts on Baxter International (BAX) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $47 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $50.57 with an expected fluctuation of $4.54 from the mean.


Company shares have received an average consensus rating of Hold for the current week Also, UBS maintains their rating on the shares of Baxter International (NYSE:BAX). The current rating of the shares is Neutral. Equity Analysts at the Firm raises the price target to $50 per share from $48 per share. The rating by the firm was issued on July 28, 2016.

Baxter International (NYSE:BAX): stock was range-bound between the intraday low of $45.77 and the intraday high of $46.13 after having opened at $45.85 on Wednesdays session. The stock finally closed in the red at $45.85, a loss of -0.11%. The stock remained in the red for the whole trading day. The total traded volume was 3,992,677 shares. The stock failed to cross $46.13 in Wednesdays trading. The stocks closing price on Thursday was $45.95.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.